Cost-effectiveness of a fecal calprotectin guided referral strategy for children with chronic abdominal symptoms
British Journal of General Practice · 2025
DOI: 10.3399/bjgp.2025.0334 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of General Practice, 2025. Verfasst von Sophie M Ansems und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Primary and Long-term Care, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Referral and Consultation, Feces, Abdominal Pain. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Triage of children with chronic abdominal symptoms who benefit from pediatric specialist care is challenging for general practitioners (GPs).
Aim
To evaluate (cost-)effectiveness of fecal calprotectin (FCal)-testing to guide referral to specialist care in children with chronic abdominal symptoms.
Methods
Pragmatic, cluster-randomized controlled trial with 1:1 randomization of Dutch GP practices between October 2019 and July 2021. GPs in the intervention group followed an FCal-guided referral strategy and the control group Dutch GP guidelines, which do not recommend FCal-testing. Eighty-four GP practices included 405 children aged 4-18 years with chronic abdominal pain and/or diarrhoea. Primary outcome was specialist referral within 6 months after baseline consultation. Incremental cost-effectiveness ratios (ICERs) were calculated from the societal perspective based on parental concern. Intention-to-treat (ITT) analyses and per-protocol (PP) analyses (strategy adherence in intervention group and no FCal use in control group) were conducted.
Results
Adherence to FCal-strategy was 59%. Alarm symptoms for IBD were more prevalent in the intervention (26.6%) than the control group (8.9%) with similar referral rates in the ITT analysis (22.8 vs 21.9%; adjusted odds ratio (aOR) 0.94, 95%CI 0.57-1.54) and fewer referrals for the intervention group in the PP analysis (5.8% vs 20.3%; aOR 0.21, 95%CI 0.09-0.50). The intervention was not cost-effective in the ITT analysis (ICER €1534; 95%CI -€9019-€9579), but cost-effective in the PP analysis (ICER -€344; 95 %CI -€4609-€3096).
Conclusion
The results do not justify recommending FCal testing in children in primary care without proper implementation. Additional research should focus on improving adherence to the FCal-strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Primary and Long-term Care, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Paediatric Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Primary and Long-term Care, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands g.a.holtman@umcg.nl.
ORCID-Profile: Sophie M Ansems, Marjolein Y Berger, Patrick F van Rheenen, Karin M Vermeulen, Michiel R de Boer, Gea A Holtman
Zitieren
APA
Ansems, S. M., Berger, M. Y., van Rheenen, P. F., Vermeulen, K. M., de Boer, M. R., & Holtman, G. A. (2025). Cost-effectiveness of a fecal calprotectin guided referral strategy for children with chronic abdominal symptoms. British Journal of General Practice. https://doi.org/10.3399/bjgp.2025.0334
Vancouver
Ansems SM, Berger MY, van Rheenen PF, Vermeulen KM, de Boer MR, Holtman GA. Cost-effectiveness of a fecal calprotectin guided referral strategy for children with chronic abdominal symptoms. British Journal of General Practice. 2025. doi:10.3399/bjgp.2025.0334
BibTeX
@article{Ansems2025,
author = {Ansems, Sophie M and Berger, Marjolein Y and van Rheenen, Patrick F and Vermeulen, Karin M and de Boer, Michiel R and Holtman, Gea A},
title = {Cost-effectiveness of a fecal calprotectin guided referral strategy for children with chronic abdominal symptoms},
journal = {British Journal of General Practice},
year = {2025},
doi = {10.3399/bjgp.2025.0334}
}
EUVIMED